IFNG and neoplasm: At 2 days after intratumoral administration of AdB7-1/IL-2, both E2-exposed tumours and placebo tumours had increased levels of IFN-γ compared with tumours injected with the control vector Addl70-3, 24±0.6 pg mg−1 tumour in AdB7-1/IL-2 vs 3±0.04 pg mg−1 tumour with the control vector.